about
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortComparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over timeIncreasing clinical virulence in two decades of the Italian HIV epidemicSurvival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyIncreased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort.Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy)Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort studyNeutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study.The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study.Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients.Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy.Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with PreserveLiver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules.Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients.Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.Screening and Management of HIV-2-Infected Individuals in Northern Italy.Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome.Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression.Predictors of AIDS-defining events among advanced naïve patients after HAART.Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
P50
Q24814420-FB041737-95C9-4AF3-A97F-05E24493B11EQ28474806-5279531E-3F58-4437-A765-85EFA2F977F4Q28475522-A6CB4758-7D0F-4623-9E6B-B71967539AFAQ28538165-663E2D71-B77E-46AE-AFFA-9C4DD4314C6BQ30869471-C9CD6FDD-5F58-4FB9-A5A1-3AD2E7F8999DQ30977187-8D6A9363-010F-4411-9AEB-50E30210907AQ33825735-0E9215CA-A75E-4957-ACC6-06E0376895A8Q34158739-C62C3C48-CEF0-4528-9890-E344B8287EB6Q34373867-23177C67-C72E-465E-9C9A-F3FFE81FEC2AQ34476753-D8641555-9AF1-4E13-893E-526C716BAF03Q34789841-6EA35276-AB58-43AC-B64A-9245FC442EAAQ35189562-3F4BF507-099B-4BF5-9FAB-0ABC8BBB7874Q36009321-8D8EB105-2DC4-475D-A08D-8F147E4C499BQ36120745-B446B0F8-7DAA-421B-A1CE-A1D417256EA2Q36309602-20B5B93E-03E8-4234-836D-767ED00CAEA0Q36347936-6CF6D344-09BE-4D68-98C3-B6901D1C0F1AQ36846855-40138509-2E18-4D0A-86A0-3F64B7D3F40AQ37141511-51106904-C979-4F0C-9AD1-FCB20F72D92EQ37605400-7FB7599F-D188-4DF8-9F33-35CFDB4F66A6Q37825500-C2443993-F3C3-400B-8413-752AC643419BQ38452529-03B53E2D-793F-45F3-B444-CA04B377363FQ38867641-DB2288D9-07D3-496F-9996-89D14961678AQ38871787-FEB83263-1E8E-4222-8AF1-F3327B70FA15Q38883681-9BA656EC-DEFB-45A6-923D-C1A2E40ACBE9Q38954366-94FC45D6-F043-42D5-9E80-43DDA4FA5B92Q38959201-7579174F-75AB-4ACF-A132-66D9CE6FE4B0Q38972140-896094C1-5A0C-4820-93B6-8168D17D08C7Q39029829-08977FDD-72BC-497C-ADC3-3B373C282EDBQ39029837-99E531EA-BBBE-4D1E-8D42-265A497ED03CQ39160263-1EEBB8FE-0D52-48E9-A024-E681F9B3F687Q39160273-BCB5CF59-07CF-4A4D-A9EB-AA85F2E3DA0FQ39160277-B8BDA5EF-1300-4C4A-BD0E-75E42DDAC52EQ39244103-053C1600-8DCB-4335-AA23-27C7BAF67AB2Q39342992-37893CD6-189D-44F2-81D7-EE1104A1B1A8Q39375453-A5F64480-3CF2-4BA5-8D2C-B3EE331C5BECQ39375459-85B93760-C7E0-4A7A-BA57-8C096BEDD0F4Q39375488-2A71ADA3-D4C2-426C-B260-2F46669EE6B0Q39530503-DECDC4AE-B453-4B48-A85A-A079AC7DC6CCQ39530512-BB937705-C960-4552-BF15-529EE4C435C8Q39530519-237410FE-2D4D-4211-9A65-360DF41867B7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eugenia Quiros-Roldan
@ast
Eugenia Quiros-Roldan
@en
Eugenia Quiros-Roldan
@es
Eugenia Quiros-Roldan
@nl
Eugenia Quiros-Roldan
@sl
type
label
Eugenia Quiros-Roldan
@ast
Eugenia Quiros-Roldan
@en
Eugenia Quiros-Roldan
@es
Eugenia Quiros-Roldan
@nl
Eugenia Quiros-Roldan
@sl
altLabel
Eugenia Quiros Roldan
@en
Maria Eugenia Quiros Roldan
@en
Maria Eugenia Quiros-Roldan
@en
prefLabel
Eugenia Quiros-Roldan
@ast
Eugenia Quiros-Roldan
@en
Eugenia Quiros-Roldan
@es
Eugenia Quiros-Roldan
@nl
Eugenia Quiros-Roldan
@sl